Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
Am Heart J
    September 2021
  1. NARCISSE DI, Ford CB, Weissler EH, Lippmann SJ, et al
    The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease.
    Am Heart J. 2021;239:135-146.
    >> Share

  2. KIM K, Yang PS, Jang E, Yu HT, et al
    Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study.
    Am Heart J. 2021 Sep 1. pii: S0002-8703(21)00224.
    >> Share

    July 2021
  3. CHRISTENSEN DM, Butt JH, Fosbol E, Kober L, et al
    Admission Rates During a Second COVID-19 Lockdown.
    Am Heart J. 2021 Jul 15. pii: S0002-8703(21)00180.
    >> Share

    June 2021
  4. ABE M, Ozaki Y, Takahashi H, Ishii M, et al
    Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy.
    Am Heart J. 2021 Jun 23. pii: S0002-8703(21)00165.
    >> Share

  5. OVERWYK K, Yin X, Tong X, Coleman King SM, et al
    Response to letters-to-the-editor for publication: "Defect-free care trends in the Paul Coverdell National Acute Stroke Program (PCNASP), 2008-2018. American Heart Journal. 2021;232:177-184. doi:10.1016/j.ahj.2020.11.010."
    Am Heart J. 2021;236:112.
    >> Share

    Re: Defect-free care trends in the Paul Coverdell National Acute Stroke Program, program, 2008-2018.
    Am Heart J. 2021;236:110-111.
    >> Share

    May 2021
  7. SIDEBOTTOM AC, Miedema MD, Benson G, Vacquier M, et al
    The Impact of a Population-based Prevention Program on Cardiovascular Events: Findings from the Heart of New Ulm Project.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00112.
    >> Share

  8. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    >> Share

  9. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    >> Share

    March 2021
  10. KIVINIEMI T, Bustamante-Munguira J, Olsson C, Jeppsson A, et al
    A randomized prospective multicenter trial for stroke prevention by prophylactic surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic valve surgery - LAA-CLOSURE trial protocol.
    Am Heart J. 2021 Mar 30. pii: S0002-8703(21)00087.
    >> Share

  11. TURAKHIA M, Sundaram V, Smith SN, Ding V, et al
    Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban
    Am Heart J. 2021 Mar 4. pii: S0002-8703(21)00065.
    >> Share

    February 2021
  12. AKAO M, Yasuda S, Kaikita K, Ako J, et al
    Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis.
    Am Heart J. 2021 Feb 28. pii: S0002-8703(21)00063.
    >> Share

  13. GE Z, Gao XF, Kan J, Kong XQ, et al
    Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicent
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00053.
    >> Share

  14. CAPELL WH, Barnathan ES, Piazza G, Spyropoulos AC, et al
    Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients with COVID-19: the PREVENT-HD Study.
    Am Heart J. 2021 Feb 9. pii: S0002-8703(21)00033.
    >> Share

  15. BLUMER V, Rivera M, Corbalan R, Becker RC, et al
    Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF.
    Am Heart J. 2021 Feb 8. pii: S0002-8703(21)00036.
    >> Share

  16. HUSAINI M, Esmaeeli A, Thangam M, Doering M, et al
    Synthesis of systematic reviews of percutaneous device closure of patent foramen ovale (PFO) for prevention of recurrent cryptogenic stroke: Redundant publications and methodological deficiencies.
    Am Heart J. 2021;232:57-60.
    >> Share

    January 2021
  17. SEN S, Redd K, Trivedi T, Moss K, et al
    Periodontal Disease, Atrial Fibrillation and Stroke.
    Am Heart J. 2021 Jan 24. pii: S0002-8703(21)00013.
    >> Share

  18. DE GROOT JR, Ruff CT, Murphy SA, Hamershock RA, et al
    Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study.
    Am Heart J. 2021 Jan 22. pii: S0002-8703(21)00017.
    >> Share

  19. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    >> Share

  20. BAO X, Borne Y, Xu B, Orho-Melander M, et al
    Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: a prospective study: Abbreviated title: GDF-15, all-cause mortality and CVD.
    Am Heart J. 2021 Jan 6. pii: S0002-8703(21)00002.
    >> Share

  21. SMILOWITZ NR, Subashchandran V, Yuriditsky E, Horowitz JM, et al
    Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19.
    Am Heart J. 2021;231:93-95.
    >> Share

  22. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    >> Share

    December 2020
  23. ROME BN, Gagne JJ, Avorn J, Kesselheim AS, et al
    Non-Warfarin Oral Anticoagulant Copayments and Adherence in Atrial Fibrillation:A Population-Based Cohort Study.
    Am Heart J. 2020 Dec 21. pii: S0002-8703(20)30412.
    >> Share

  24. CARNICELLI AP, Hong H, Giugliano RP, Connolly SJ, et al
    Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple instit
    Am Heart J. 2020 Dec 6. pii: S0002-8703(20)30401.
    >> Share

  25. KHAN H, Hanif M, Khan MA, Mirza E, et al
    Letter to the editor: Discontinuation rates of warfarin versus direct acting oral anticoagulants in clinical practice.
    Am Heart J. 2020;230:101.
    >> Share

    November 2020
  26. OVERWYK KJ, Yin X, Tong X, King SMC, et al
    Defect-free Care trends in the Paul Coverdell National Acute Stroke Program, 2008-2018.
    Am Heart J. 2020 Nov 27. pii: S0002-8703(20)30392.
    >> Share

  27. KAWASHIMA H, Soliman O, Wang R, Ono M, et al
    Rationale and design of a randomized clinical trial comparing safety and efficacy of Myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: the LANDMARK trial.
    Am Heart J. 2020 Nov 5. pii: S0002-8703(20)30368.
    >> Share

    October 2020
  28. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    >> Share

  29. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    >> Share

  30. NATHAN AS, Yang L, Geng Z, Dayoub EJ, et al
    Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair.
    Am Heart J. 2020;232:1-9.
    >> Share

  31. NICHOLLS SJ, Lincoff AM, Bays HE, Cho L, et al
    Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.
    Am Heart J. 2020 Oct 23. pii: S0002-8703(20)30346.
    >> Share

  32. SHAVADIA JS, Wilson J, Edmonston D, Platt A, et al
    Statins and atherosclerotic cardiovascular outcomes in patients on incident dialysis and with atherosclerotic heart disease.
    Am Heart J. 2020 Oct 20. pii: S0002-8703(20)30341.
    >> Share

  33. GIBSON CM, Kastelein JJP, Phillips AT, Aylward PE, et al
    Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myoc
    Am Heart J. 2020 Oct 13. pii: S0002-8703(20)30335.
    >> Share

  34. GUIMARAES HP, de Barros E Silva PGM, Liporace IL, Sampaio RO, et al
    A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.
    Am Heart J. 2020 Oct 9. pii: S0002-8703(20)30277.
    >> Share

  35. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    >> Share

    September 2020
  36. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    >> Share

  37. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    >> Share

    August 2020
  38. KAWAKAMI H, Nolan MT, Phillips K, Scuffham PA, et al
    Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Am Heart J. 2020 Aug 18. pii: S0002-8703(20)30238.
    >> Share

  39. KWON S, Lee SR, Choi EK, Choe WS, et al
    Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Am Heart J. 2020;229:81-91.
    >> Share

  40. ELHARRAM M, Sharma A, White W, Bakris G, et al
    Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
    Am Heart J. 2020;229:40-51.
    >> Share

  41. MIRWAIS M, Reynolds M
    Extending physicians' reach in grasping AF symptoms.
    Am Heart J. 2020;226:250-251.
    >> Share

    July 2020
  42. AL-KHATIB SM, Pokorney SD, Al-Khalidi HR, Haynes K, et al
    Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillati
    Am Heart J. 2020;229:110-117.
    >> Share

  43. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    >> Share

    May 2020
  44. ARMSTRONG PW, Bogaerts K, Welsh R, Sinnaeve PR, et al
    The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
    Am Heart J. 2020;226:140-146.
    >> Share

    April 2020
  45. JACKSON LR 2ND, Kim S, Blanco R, Thomas L, et al
    Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2020;226:85-93.
    >> Share

  46. WHITE HD, Stewart RAH, Dalby AJ, Stebbins A, et al
    In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c <7% are associated with lower major cardiovascular events.
    Am Heart J. 2020;225:97-107.
    >> Share

  47. YANG Y, Zhou Z, Pan Y, Chen H, et al
    Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design.
    Am Heart J. 2020;225:38-43.
    >> Share

  48. EHRLICH ME, Kolls BJ, Roettig M, Monk L, et al
    Implementation of Best Practices-Developing and Optimizing Regional Systems of Stroke Care: Design and Methodology.
    Am Heart J. 2020;222:105-111.
    >> Share

    March 2020
  49. KARTHIKEYAN G, Connolly SJ, Ntsekhe M, Benz A, et al
    The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
    Am Heart J. 2020;225:69-77.
    >> Share

  50. THIBERT MJ, Hawkins NM, Andrade JG
    Clinical decision support for atrial fibrillation in primary care: Steps forward.
    Am Heart J. 2020;224:54-56.
    >> Share

  51. HUANG L, Tian M, Yu J, Li Q, et al
    Interim effects of salt substitution on urinary electrolytes and blood pressure in the China Salt Substitute and Stroke Study (SSaSS).
    Am Heart J. 2020;221:136-145.
    >> Share

  52. GESKE JB, Driver CN, Yogeswaran V, Ommen SR, et al
    Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy.
    Am Heart J. 2020;221:159-164.
    >> Share

    February 2020
  53. AKAO M, Yamashita T, Suzuki S, Okumura K, et al
    Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis.
    Am Heart J. 2020;223:23-33.
    >> Share

    January 2020
  54. WEIR MR, Ashton V, Moore KT, Shrivastava S, et al
    Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease.
    Am Heart J. 2020;223:3-11.
    >> Share

    Atrial fibrillation detection using implantable cardiac monitors: Are we being too revealing?
    Am Heart J. 2020;219:137-139.
    >> Share

  56. REIFFEL JA, Verma A, Kowey PR, Halperin JL, et al
    Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study.
    Am Heart J. 2020;219:128-136.
    >> Share

  57. CASSESE S, Ndrepepa G, Byrne RA, Laugwitz KL, et al
    Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials.
    Am Heart J. 2020;219:109-116.
    >> Share

  58. SAMSKY M, Krucoff M, Althouse AD, Abraham WT, et al
    Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
    Am Heart J. 2020;219:1-8.
    >> Share

    December 2019
  59. SALAHUDDIN T, Kittelson J, Tardif JC, Shah PK, et al
    Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
    Am Heart J. 2019;221:60-66.
    >> Share

  60. MAZUREK M, Teutsch C, Diener HC, Dubner SJ, et al
    Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
    Am Heart J. 2019;218:123-127.
    >> Share

    November 2019
  61. DE FERRARI GM, Stevens SR, Ambrosio G, Leonardi S, et al
    Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;220:82-88.
    >> Share

  62. MAGGIONI AP, Dondi L, Andreotti F, Pedrini A, et al
    Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people.
    Am Heart J. 2019;220:12-19.
    >> Share

  63. EVANS CR, Long DL, Howard G, McClure LA, et al
    C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort.
    Am Heart J. 2019;217:94-100.
    >> Share

    October 2019
  64. GARCIA DA, Fisher DA, Mulder H, Wruck L, et al
    Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2019;221:1-8.
    >> Share

  65. WELSH RC, Peterson ED, De Caterina R, Bode C, et al
    Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
    Am Heart J. 2019;218:100-109.
    >> Share

  66. POKORNEY SD, Holmes DN, Shrader P, Thomas L, et al
    Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation.
    Am Heart J. 2019;220:145-154.
    >> Share

  67. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    >> Share

  68. NIDORF SM, Fiolet ATL, Eikelboom JW, Schut A, et al
    The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Am Heart J. 2019;218:46-56.
    >> Share

  69. PAGIDIPATI NJ, Zheng Y, Green JB, McGuire DK, et al
    Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;219:47-57.
    >> Share

  70. JONES WS, Kennedy KF, Hawkins BM, Attaran RR, et al
    Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.
    Am Heart J. 2019;216:74-81.
    >> Share

    September 2019
  71. BRENNAN JM, Wruck L, Pencina MJ, Clare RM, et al
    Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
    Am Heart J. 2019;218:110-122.
    >> Share

    August 2019
  72. PARK S, Ahn JM, Lee K, Kwon O, et al
    Long-term (10-year) outcomes of stenting or bypass surgery for acute coronary syndromes and stable ischemic heart disease with unprotected left main coronary artery disease.
    Am Heart J. 2019;218:9-19.
    >> Share

  73. RAY KK, Nicholls SJ, Ginsberg HD, Johansson JO, et al
    Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Am Heart J. 2019;217:72-83.
    >> Share

    June 2019
  74. CANNON CP, Khan I, Klimchak AC, Sanchez RJ, et al
    Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Am Heart J. 2019;216:30-41.
    >> Share

  75. OSTERGAARD L, Andersson NW, Kristensen SL, Dahl A, et al
    Risk of stroke subsequent to infective endocarditis: A nationwide study.
    Am Heart J. 2019;212:144-151.
    >> Share

    May 2019
  76. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
    Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
    Am Heart J. 2019;214:97-106.
    >> Share

  77. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    >> Share

  78. GAZIANO TA, Pandya A, Sy S, Jardim TV, et al
    Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Am Heart J. 2019;214:77-87.
    >> Share

    April 2019
  79. INOHARA T, Shrader P, Pieper K, Blanco RG, et al
    Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
    Am Heart J. 2019;213:81-90.
    >> Share

  80. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    >> Share

  81. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    >> Share

  82. HAAS S, Camm AJ, Bassand JP, Angchaisuksiri P, et al
    Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Am Heart J. 2019;213:35-46.
    >> Share

    February 2019
  83. PETERSON ED, Ashton V, Chen YW, Wu B, et al
    Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Am Heart J. 2019;212:113-119.
    >> Share

    January 2019
  84. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    >> Share

  85. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    >> Share

  86. MACHLINE-CARRION MJ, Santucci EV, Damiani LP, Bahit C, et al
    An international cluster-randomized quality improvement trial to increase the adherence to evidence-based therapies for acute ischemic stroke and transient ischemic attack patients: Rationale and design of the BRIDGE STROKE Trial.
    Am Heart J. 2019;207:49-57.
    >> Share

  87. GONG E, Gu W, Sun C, Turner EL, et al
    System-integrated technology-enabled model of care to improve the health of stroke patients in rural China: protocol for SINEMA-a cluster-randomized controlled trial.
    Am Heart J. 2019;207:27-39.
    >> Share

    November 2018
  88. ALEXANDER KP, Brouwer MA, Mulder H, Vinereanu D, et al
    Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial.
    Am Heart J. 2018 Nov 22. pii: S0002-8703(18)30296.
    >> Share

  89. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    >> Share

    October 2018
  90. POKORNEY SD, Gersh BJ, Ahmad A, Al-Khatib SM, et al
    Stroke prevention in atrial fibrillation: Closing the gap.
    Am Heart J. 2018;210:29-38.
    >> Share

  91. DAVISON WJ, Myint PK, Clark AB, Potter JF, et al
    Blood pressure differences between home monitoring and daytime ambulatory values and their reproducibility in treated hypertensive stroke and TIA patients.
    Am Heart J. 2018;207:58-65.
    >> Share

  92. BEINART SC, Natale A, Verma A, Amin A, et al
    Real-world comparison of in-hospital Reveal LINQ insertable cardiac monitor insertion inside and outside of the cardiac catheterization or electrophysiology laboratory.
    Am Heart J. 2018 Oct 14. pii: S0002-8703(18)30295.
    >> Share

    July 2018
    Atrial fibrillation and stroke: The more we learn, the less we understand.
    Am Heart J. 2018;201:158-159.
    >> Share

    June 2018
  94. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    >> Share

  95. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    >> Share

  96. LUBITZ SA, Khurshid S, Weng LC, Doros G, et al
    Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk.
    Am Heart J. 2018;200:24-31.
    >> Share

  97. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    >> Share

  98. CHEN ST, Hellkamp AS, Becker RC, Berkowitz SD, et al
    Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.
    Am Heart J. 2018;200:102-109.
    >> Share

    May 2018
  99. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    >> Share

    April 2018
  100. HUISMAN MV, Rothman KJ, Paquette M, Teutsch C, et al
    Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Am Heart J. 2018;198:55-63.
    >> Share

  101. HIJAZI Z, Hohnloser SH, Oldgren J, Andersson U, et al
    Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
    Am Heart J. 2018;198:169-177.
    >> Share

  102. MIYAZAWA K, Pastori D, Lip GYH
    Changes in renal function in patients with atrial fibrillation: Efficacy and safety of the non-vitamin K antagonist oral anticoagulants.
    Am Heart J. 2018;198:166-168.
    >> Share

    March 2018
  103. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    >> Share

  104. RIVERA-CARAVACA JM, Roldan V, Esteve-Pastor MA, Valdes M, et al
    Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED.
    Am Heart J. 2018;197:27-34.
    >> Share

  105. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    >> Share

  106. VERMA A, Ha ACT, Kirchhof P, Hindricks G, et al
    The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.
    Am Heart J. 2018;197:124-132.
    >> Share

  107. FANNING JP, Wesley AJ, Walters DL, Wong AA, et al
    Topographical distribution of perioperative cerebral infarction associated with transcatheter aortic valve implantation.
    Am Heart J. 2018;197:113-123.
    >> Share

  108. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    >> Share

  109. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    >> Share

    January 2018
  110. YONG CM, Liu Y, Apruzzese P, Doros G, et al
    Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry.
    Am Heart J. 2018;195:50-59.
    >> Share

  111. CLARK NP, Douketis JD, Hasselblad V, Schulman S, et al
    Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial.
    Am Heart J. 2018;195:108-114.
    >> Share

    December 2017
  112. OKUMURA K, Lip GYH, Akao M, Tanizawa K, et al
    Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Am Heart J. 2017;194:99-106.
    >> Share

  113. STEINBERG BA, Gao H, Shrader P, Pieper K, et al
    International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Am Heart J. 2017;194:132-140.
    >> Share

    November 2017
  114. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    >> Share

    October 2017
  115. MOJOLI M, Gersh BJ, Barioli A, Masiero G, et al
    Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis.
    Am Heart J. 2017;192:64-75.
    >> Share

  116. VINEREANU D, Al-Khalidi HR, Rao MP, He W, et al
    Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF
    Am Heart J. 2017;192:38-47.
    >> Share

  117. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    >> Share

    September 2017
  118. O'NEILL ES, Grande SW, Sherman A, Elwyn G, et al
    Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review.
    Am Heart J. 2017;191:1-11.
    >> Share

    August 2017
  119. HIJAZI Z, Oldgren J, Andersson U, Connolly SJ, et al
    Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Am Heart J. 2017;190:94-103.
    >> Share

  120. BERNSTEIN RA, Kamel H, Granger CB, Kowal RC, et al
    Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.
    Am Heart J. 2017;190:19-24.
    >> Share

  121. KIRCHHOF P, Blank BF, Calvert M, Camm AJ, et al
    Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Am Heart J. 2017;190:12-18.
    >> Share

    July 2017
  122. HOLMES DR, Reddy VY, Buchbinder M, Stein K, et al
    The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial.
    Am Heart J. 2017;189:68-74.
    >> Share

  123. STEINBERG BA, Shrader P, Thomas L, Ansell J, et al
    Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2017;189:40-47.
    >> Share

    June 2017
  124. NEAL B, Tian M, Li N, Elliott P, et al
    Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)-A large-scale cluster randomized controlled trial.
    Am Heart J. 2017;188:109-117.
    >> Share

    May 2017
  125. KARLSSON LO, Nilsson S, Charitakis E, Bang M, et al
    Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting.
    Am Heart J. 2017;187:45-52.
    >> Share

  126. HESS CN, Clare RM, Neely ML, Tricoci P, et al
    Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
    Am Heart J. 2017;187:194-203.
    >> Share

  127. DIEDERICHSEN SZ, Haugan KJ, Kober L, Hojberg S, et al
    Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.
    Am Heart J. 2017;187:122-132.
    >> Share

  128. MENTZ RJ, Bethel MA, Gustavson S, Thompson VP, et al
    Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Am Heart J. 2017;187:1-9.
    >> Share

    April 2017
  129. DUCROCQ G, Schulte PJ, Budaj A, Cornel JH, et al
    Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
    Am Heart J. 2017;186:91-99.
    >> Share

    March 2017
  130. NAKANISHI K, Jin Z, Homma S, Elkind MS, et al
    Left ventricular mass-geometry and silent cerebrovascular disease: The Cardiovascular Abnormalities and Brain Lesions (CABL) study.
    Am Heart J. 2017;185:85-92.
    >> Share

  131. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    >> Share

  132. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    >> Share

  133. HUFFMAN MD, Mohanan PP, Devarajan R, Baldridge AS, et al
    Acute coronary syndrome quality improvement in Kerala (ACS QUIK): Rationale and design for a cluster-randomized stepped-wedge trial.
    Am Heart J. 2017;185:154-160.
    >> Share

  134. WESTENBRINK BD, Alings M, Granger CB, Alexander JH, et al
    Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2017;185:140-149.
    >> Share

    February 2017
  135. ARMSTRONG PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, et al
    Corrigendum to "Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial" [Am Heart J 169/6 (2015) 890-898].
    Am Heart J. 2017;184:157.
    >> Share

  136. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    >> Share

  137. BERWANGER O, de Barros E Silva PG, Barbosa RR, Precoma DB, et al
    Atorvastatin for high-risk statin-naive patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial.
    Am Heart J. 2017;184:88-96.
    >> Share

  138. KHAN H, Jaffar N, Rauramaa R, Kurl S, et al
    Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study.
    Am Heart J. 2017;184:55-61.
    >> Share

    January 2017
  139. OSMANCIK P, Tousek P, Herman D, Neuzil P, et al
    Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study).
    Am Heart J. 2017;183:108-114.
    >> Share

    November 2016
  140. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    >> Share

  141. STEINBERG BA, Shrader P, Kim S, Thomas L, et al
    How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Am Heart J. 2016;181:145-152.
    >> Share

  142. VALENTINO M, Al Danaf J, Panakos A, Ragupathi L, et al
    Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Am Heart J. 2016;181:130-136.
    >> Share

  143. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    >> Share

    October 2016
  144. WINDECKER S, Tijssen J, Giustino G, Guimaraes AH, et al
    Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Am Heart J. 2016;184:81-87.
    >> Share

  145. ALLEN JE, Knight S, McCubrey RO, Bair T, et al
    beta-blocker dosage and outcomes after acute coronary syndrome.
    Am Heart J. 2016;184:26-36.
    >> Share

  146. VAN DER MEERSCH H, De Bacquer D, De Vriese AS
    Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Am Heart J. 2016;184:37-46.
    >> Share

    September 2016
  147. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    >> Share

  148. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
    Am Heart J. 2016;179:175-83.
    >> Share

  149. TROXEL AB, Asch DA, Mehta SJ, Norton L, et al
    Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program.
    Am Heart J. 2016;179:166-74.
    >> Share

  150. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    >> Share

  151. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    >> Share

  152. EZEKOWITZ MD, Pollack CV, Sanders P, Halperin JL, et al
    Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
    Am Heart J. 2016;179:59-68.
    >> Share

    May 2016
    Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?
    Am Heart J. 2016;175:168-71.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016